FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $195 | -92.4% | 91,864 | -82.9% | 0.01% | -91.9% |
| Q2 2023 | $2,555 | +17.8% | 536,831 | +41.1% | 0.11% | +8.8% |
| Q1 2023 | $2,169 | -99.7% | 380,537 | +1681.9% | 0.10% | +88.9% |
| Q1 2022 | $828,000 | +55.3% | 21,356 | +134.4% | 0.05% | -19.4% |
| Q4 2021 | $533,000 | +13.6% | 9,111 | +15.0% | 0.07% | +8.1% |
| Q3 2021 | $469,000 | +172.7% | 7,921 | -54.9% | 0.06% | +87.9% |
| Q1 2018 | $172,000 | -38.6% | 17,580 | -75.1% | 0.03% | -48.4% |
| Q3 2017 | $280,000 | -15.4% | 70,677 | -30.8% | 0.06% | -31.2% |
| Q2 2017 | $331,000 | – | 102,169 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |